APA (7th ed.) Citation

Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., . . . Cottin, V. (2018). Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: Design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research, 5, . https://doi.org/10.1136/bmjresp-2018-000289

Chicago Style (17th ed.) Citation

Maher, Toby M., Tamera J. Corte, Aryeh Fischer, Michael Kreuter, David J. Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, and Vincent Cottin. "Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: Design of a Double-blind, Randomised, Placebo-controlled Phase II Trial." BMJ Open Respiratory Research 5 (2018). https://doi.org/10.1136/bmjresp-2018-000289.

MLA (9th ed.) Citation

Maher, Toby M., et al. "Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: Design of a Double-blind, Randomised, Placebo-controlled Phase II Trial." BMJ Open Respiratory Research, vol. 5, 2018, https://doi.org/10.1136/bmjresp-2018-000289.